Systemic Sclerosis (Scleroderma) Pipeline Review, H2 2018 - Therapeutic Assessment of 43 Companies & Drug Profiles - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 15, 9, 1, 31 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Systemic Sclerosis (Scleroderma) - Overview Systemic Sclerosis (Scleroderma) - Therapeutics Development Systemic Sclerosis (Scleroderma) - Therapeutics Assessment Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development Systemic Sclerosis (Scleroderma) - Drug Profiles Systemic Sclerosis (Scleroderma) - Dormant Projects Systemic Sclerosis (Scleroderma) - Discontinued Products Systemic Sclerosis (Scleroderma) - Product Development Milestones Appendix Abide Therapeutics Inc AnaMar AB Anima Biotech Ltd arGentis Pharmaceuticals LLC Bayer AG Biogen Inc Boehringer Ingelheim GmbH BriaCell Therapeutics Corp Bristol-Myers Squibb Co Capella Bioscience Ltd Chugai Pharmaceutical Co Ltd Covis Pharmaceuticals Inc CSL Ltd Cumberland Pharmaceuticals Inc F. Hoffmann-La Roche Ltd Fibrocell Science Inc Formation Biologics Inc Fresenius SE & Co KGaA GenKyoTex SA Gilead Sciences Inc GlaxoSmithKline Plc Link Genomics Inc MallInckrodt Plc Nuevolution AB Patagonia Pharmaceuticals LLC PDX Pharmaceuticals LLC Peptinov SAS Pfizer Inc ProMetic Life Sciences Inc Sanofi Seattle Genetics Inc Stemline Therapeutics Inc Takeda Pharmaceutical Co Ltd Unity Biotechnology Inc Vicore Pharma AB
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/crqth8/systemic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006087/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs,Immune Disorders Drugs,Dermatological Drugs,Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/26/2018 06:04 PM/DISC: 09/26/2018 06:04 PM